{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:11:38Z","timestamp":1772781098283,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1053\/beog.2000.0189","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T13:54:50Z","timestamp":1032443690000},"page":"469-489","source":"Crossref","is-referenced-by-count":13,"title":["Hormonal treatment of endometrial cancer: past, present and future"],"prefix":"10.1053","volume":"15","author":[{"given":"Edward","family":"Podczaski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigue","family":"Mortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beog.2000.0189_RF1","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/1097-0142(195911\/12)12:6<1106::AID-CNCR2820120607>3.0.CO;2-M","article-title":"Histologic effects of progestins on hyperplasia and carcinoma in situ of the endometrium","volume":"12","author":"Kistner","year":"1959","journal-title":"Cancer"},{"key":"10.1053\/beog.2000.0189_RF2","article-title":"Effects of 17-alpha-hydroxy progesterone caproate on metastatic endometrial cancer","volume":"Monograph 9:235\u2013241","author":"Baker","year":"1960","journal-title":"Conference on Experimental Clinical Cancer Chemotherapy"},{"key":"10.1053\/beog.2000.0189_RF3","first-page":"1190","article-title":"The role of progesterone in human endometrial cancer","volume":"25","author":"Kelley","year":"1965","journal-title":"Cancer Research"},{"key":"10.1053\/beog.2000.0189_RF4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jama.1963.03700230058009","article-title":"A progestogen for treatment of advanced endometrial cancer","volume":"184","author":"Kennedy","year":"1963","journal-title":"Journal of the American Medical Association"},{"key":"10.1053\/beog.2000.0189_RF5","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1126\/science.3753802","article-title":"Sequence and expression of human estrogen receptor complementary DNA","volume":"231","author":"Greene","year":"1986","journal-title":"Science"},{"key":"10.1053\/beog.2000.0189_RF6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.3283939","article-title":"The steroid and thyroid hormone receptor superfamily","volume":"240","author":"Evans","year":"1988","journal-title":"Science"},{"key":"10.1053\/beog.2000.0189_RF7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/j.1460-2075.1992.tb05139.x","article-title":"Evolution of the nuclear receptor gene superfamily","volume":"11","author":"Laudet","year":"1982","journal-title":"European Molecular Biology Organization Journal"},{"key":"10.1053\/beog.2000.0189_RF8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0168-9525(88)90108-4","article-title":"Nuclear receptors enhance our understanding of transcription regulation","volume":"4","author":"Green","year":"1988","journal-title":"Trends in Genetics"},{"key":"10.1053\/beog.2000.0189_RF9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0083-6729(08)60408-2","article-title":"The molecular pharmacology of ovarian steroid receptors","volume":"52","author":"Vegeto","year":"1996","journal-title":"Vitamins and Hormones"},{"key":"10.1053\/beog.2000.0189_RF10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(89)90052-4","article-title":"Mechanism of nuclear localization of the progesterone receptor: Evidence for interaction between monomers","volume":"57","author":"Guiochon-Mantel","year":"1989","journal-title":"Cell"},{"key":"10.1053\/beog.2000.0189_RF11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/nar\/16.2.647","article-title":"A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor","volume":"16","author":"Klein-Hitpass","year":"1988","journal-title":"Nucleic Acids Research"},{"key":"10.1053\/beog.2000.0189_RF12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2826.1993.tb00476.x","article-title":"Structure and function of the oestrogen receptor","volume":"5","author":"Parker","year":"1993","journal-title":"Journal of Neuroendocrinology"},{"key":"10.1053\/beog.2000.0189_RF13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/348458a0","article-title":"Solution structure of the DNA-binding domain of the oestrogen receptor","volume":"348","author":"Schwabe","year":"1990","journal-title":"Nature"},{"key":"10.1053\/beog.2000.0189_RF14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nsb0196-87","article-title":"A canonical structure for the ligand-binding domain of nuclear receptors","volume":"3","author":"Wurtz","year":"1996","journal-title":"Nature Structural Biology"},{"key":"10.1053\/beog.2000.0189_RF15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/387043a0","article-title":"A complex containing N-CoR, mSin3, and histone deacetylase mediates transcriptional repression","volume":"387","author":"Heinzel","year":"1997","journal-title":"Nature"},{"key":"10.1053\/beog.2000.0189_RF16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/387016a0","article-title":"Sinful repression","volume":"387","author":"Wolffe","year":"1997","journal-title":"Nature"},{"key":"10.1053\/beog.2000.0189_RF17","doi-asserted-by":"crossref","first-page":"16433","DOI":"10.1016\/S0021-9258(17)34025-5","article-title":"Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer","volume":"269","author":"Umayahara","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.1053\/beog.2000.0189_RF18","first-page":"443","article-title":"Tamoxifen activation of the estrogen receptor\/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens","volume":"9","author":"Webb","year":"1995","journal-title":"Molecular Endocrinology"},{"key":"10.1053\/beog.2000.0189_RF19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-5793(96)00782-X","article-title":"ER\u03b2: identification and characterization of a novel human estrogen receptor","volume":"392","author":"Mosselman","year":"1996","journal-title":"FEBS Letters"},{"key":"10.1053\/beog.2000.0189_RF20","first-page":"4258","article-title":"Human estrogen receptor \u03b2-gene structure, chromosomal localization, and expression pattern","volume":"82","author":"Enmark","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beog.2000.0189_RF21","doi-asserted-by":"crossref","first-page":"19858","DOI":"10.1074\/jbc.272.32.19858","article-title":"Estrogen receptors \u03b1 and \u03b2 form heterodimers on DNA","volume":"272","author":"Cowley","year":"1997","journal-title":"Journal of Biological Chemistry"},{"key":"10.1053\/beog.2000.0189_RF22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/bbrc.1997.7893","article-title":"The complete primary structure of human estrogen receptor \u03b2 (hER\u03b2) and its heterodimerization with ER \u03b1 in vivo and in vitro","volume":"243","author":"Ogawa","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1053\/beog.2000.0189_RF23","first-page":"741","article-title":"Endometrial adenocarcinoma in women under 25 years of age","volume":"68","author":"Farhi","year":"1986","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2","article-title":"Progestin alone as primary treatment of endometrial carcinoma in premenopausal women","volume":"79","author":"Kim","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/beog.2000.0189_RF25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0029-7844(97)00297-4","article-title":"Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40","volume":"90","author":"Randall","year":"1997","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0015-0282(16)53840-0","article-title":"Pregnancy after in vitro fertilization in a patient with stage I endometrial carcinoma treated with progestins","volume":"54","author":"Paulson","year":"1990","journal-title":"Fertility and Sterility"},{"key":"10.1053\/beog.2000.0189_RF27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1525-1438.1998.97100.x","article-title":"Endometrial carcinoma Stage I\u2014Grade II. Conservative treatment followed by a healthy twin pregnancy","volume":"8","author":"Zuckerman","year":"1998","journal-title":"International Journal of Gynecologic Cancer"},{"key":"10.1053\/beog.2000.0189_RF28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0090-8258(74)90028-6","article-title":"Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer","volume":"2","author":"Lewis","year":"1974","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1471-0528.1988.tb06847.x","article-title":"A randomized trial of progestogens in the primary treatment of endometrial carcinoma","volume":"95","author":"Macdonald","year":"1988","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beog.2000.0189_RF30","first-page":"121","article-title":"A controlled clinical study of adjuvant medroxyprogesterone acetate (MPA) therapy in pathologic stage I endometrial carcinoma with myometrial invasion","volume":"4","author":"De Palo","year":"1985","journal-title":"Proceedings of the American Society of Clincial Oncology"},{"key":"10.1053\/beog.2000.0189_RF31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/1097-0142(19890901)64:5<1011::AID-CNCR2820640507>3.0.CO;2-7","article-title":"A randomized trial of adjuvant progestagen in early endometrial cancer","volume":"64","author":"Vergote","year":"1989","journal-title":"Cancer"},{"key":"10.1053\/beog.2000.0189_RF32","first-page":"98","article-title":"Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial","volume":"14","author":"Urbanski","year":"1993","journal-title":"European Journal of Gynaecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/1097-0142(19800115)45:2<268::AID-CNCR2820450211>3.0.CO;2-8","article-title":"Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma","volume":"45","author":"Piver","year":"1980","journal-title":"Cancer"},{"key":"10.1053\/beog.2000.0189_RF34","first-page":"106","article-title":"Effects of progestational agents in treatment of endometrial carcinoma","volume":"66","author":"Podratz","year":"1985","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF35","series-title":"Endocrinology and Malignancy: Basic and Clinical Issues","first-page":"446","article-title":"Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels. The Gynecologic Oncology Group experience","author":"Thigpen","year":"1986"},{"key":"10.1053\/beog.2000.0189_RF36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9378(16)32990-8","article-title":"A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma","volume":"135","author":"Sall","year":"1979","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/00016348409156700","article-title":"Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations","volume":"63","author":"Kauppila","year":"1984","journal-title":"Acta Obstetrica et Gynaecologica Scandinavica"},{"key":"10.1053\/beog.2000.0189_RF38","first-page":"185","article-title":"A randomized trial of medroxyprogesterone acetate (MPA) 200mg versus 1000mg daily in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group (GOG) study","volume":"10","author":"Thigpen","year":"1991","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1053\/beog.2000.0189_RF39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.1996.14.2.357","article-title":"High-dose megesterol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"14","author":"Lentz","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beog.2000.0189_RF40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ijc.2910240505","article-title":"Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration","volume":"24","author":"Janne","year":"1979","journal-title":"International Journal of Cancer"},{"key":"10.1053\/beog.2000.0189_RF41","first-page":"1140","article-title":"Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to antiestrogen","volume":"41","author":"Mortel","year":"1981","journal-title":"Cancer Research"},{"key":"10.1053\/beog.2000.0189_RF42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0002-9378(84)90243-6","article-title":"Plasma steroid hormones, cytosol receptors, and thymidine incorporation rate in endometrial carcinoma","volume":"149","author":"Lindahl","year":"1984","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF43","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0002-9378(88)90075-0","article-title":"Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium","volume":"158","author":"Ehrlich","year":"1988","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF44","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/1097-0142(19821115)50:10<2157::AID-CNCR2820501031>3.0.CO;2-7","article-title":"Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestin. Clinical correlates","volume":"50","author":"Kauppila","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/beog.2000.0189_RF45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ijc.2910230309","article-title":"Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy","volume":"23","author":"Martin","year":"1979","journal-title":"International Journal of Cancer"},{"key":"10.1053\/beog.2000.0189_RF46","first-page":"171","article-title":"Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma","volume":"96","author":"McCarty","year":"1979","journal-title":"American Journal of Pathology"},{"key":"10.1053\/beog.2000.0189_RF47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0046-8177(98)80002-6","article-title":"Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen and progesterone receptor expression","volume":"29","author":"Lax","year":"1988","journal-title":"Human Pathology"},{"key":"10.1053\/beog.2000.0189_RF48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/00016348009154633","article-title":"Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?","volume":"59","author":"Benraad","year":"1980","journal-title":"Acta Obstetrica et Gynecologica Scandinavica"},{"key":"10.1053\/beog.2000.0189_RF49","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0002-9378(15)33275-0","article-title":"Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications","volume":"141","author":"Ehrlich","year":"1981","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF50","first-page":"1889","article-title":"Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma","volume":"48","author":"Zaino","year":"1988","journal-title":"Cancer Research"},{"key":"10.1053\/beog.2000.0189_RF51","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beog.2000.0189_RF52","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beog.2000.0189_RF53","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/jcem-70-4-1132","article-title":"Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition","volume":"70","author":"Bagdade","year":"1990","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beog.2000.0189_RF54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","article-title":"Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers","volume":"i","author":"Fornander","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/beog.2000.0189_RF55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1053\/beog.2000.0189_RF56","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.277.5331.1508","article-title":"Differential ligand activation of estrogen receptors ER\u03b1 and ER\u03b2 at AP-1 sites","volume":"277","author":"Paech","year":"1997","journal-title":"Science"},{"key":"10.1053\/beog.2000.0189_RF57","first-page":"659","article-title":"Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens","volume":"9","author":"McDonnell","year":"1995","journal-title":"Molecular Endocrinology"},{"key":"10.1053\/beog.2000.0189_RF58","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"387","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"10.1053\/beog.2000.0189_RF59","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.270.5240.1354","article-title":"Sequence and characterization of a coactivator for the steroid hormone receptor superfamily","volume":"270","author":"Onate","year":"1995","journal-title":"Science"},{"key":"10.1053\/beog.2000.0189_RF60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/mend.11.6.0009","article-title":"Coactivator and corepressor regulation of the agonist\/antagonist activity of the mixed antiestrogen, 4-hydroxy-tamoxifen","volume":"11","author":"Smith","year":"1997","journal-title":"Molecular Endocrinology"},{"key":"10.1053\/beog.2000.0189_RF61","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/mend.11.6.0004","article-title":"The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7\/SPA and the corepressors N-CoR or SMRT","volume":"11","author":"Jackson","year":"1997","journal-title":"Molecular Endocrinology"},{"key":"10.1053\/beog.2000.0189_RF62","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1991.9.6.1071","article-title":"Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions","volume":"9","author":"Moore","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beog.2000.0189_RF63","first-page":"1019","article-title":"Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment","volume":"70","author":"Edmonson","year":"1986","journal-title":"Cancer Treatment Reports"},{"key":"10.1053\/beog.2000.0189_RF64","first-page":"809","article-title":"Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"68","author":"Slavik","year":"1984","journal-title":"Cancer Treatment Reports"},{"key":"10.1053\/beog.2000.0189_RF65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0002-9378(84)90187-X","article-title":"Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia","volume":"149","author":"Carlson","year":"1984","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF66","first-page":"261","article-title":"Phase II study of megestrol (M) and megestrol+tamoxifen (T) in advanced endometrial carcinoma: an Eastern Cooperative Oncology Group (ECOG) study","volume":"30","author":"Pandya","year":"1989","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1053\/beog.2000.0189_RF67","first-page":"327","article-title":"Treatment of recurrent or metastatic poorly differentiated adenocarcinomas of the endometrium with tamoxifen and medroxyprogesterone acetate","volume":"71","author":"Kline","year":"1987","journal-title":"Cancer Treatment Reports"},{"key":"10.1053\/beog.2000.0189_RF68","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/0277-5379(89)90307-6","article-title":"Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate","volume":"25","author":"Tatman","year":"1989","journal-title":"European Journal of Cancer and Clinical Oncology"},{"key":"10.1053\/beog.2000.0189_RF69","first-page":"1458","article-title":"High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines","volume":"77","author":"Emons","year":"1993","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beog.2000.0189_RF70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0002-9378(94)70391-4","article-title":"Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis","volume":"170","author":"Kleinman","year":"1994","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF71","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1471-0528.1991.tb15343.x","article-title":"A new treatment for endometrial cancer with gonadotropin releasing-hormone analogue","volume":"98","author":"Gallagher","year":"1991","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beog.2000.0189_RF72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/gyno.1996.0276","article-title":"Long-term follow-up of gonadotropin-releasing hormone analog treatment for recurrent endometrial cancer","volume":"63","author":"Jeyarajah","year":"1996","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF73","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/gyno.1996.4544","article-title":"A phase II study of leuprolide in advanced\/recurrent endometrial cancer","volume":"64","author":"Covens","year":"1997","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF74","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1006\/gyno.1997.4767","article-title":"Leuprolide in the treatment of endometrial cancer","volume":"66","author":"Markman","year":"1997","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0002-9378(81)90280-5","article-title":"Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate","volume":"140","author":"Deppe","year":"1981","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF76","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/1097-0142(19820615)49:12<2441::AID-CNCR2820491203>3.0.CO;2-Q","article-title":"Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens","volume":"49","author":"Horton","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/beog.2000.0189_RF77","first-page":"719","article-title":"Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"63","author":"Cohen","year":"1984","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF78","first-page":"557","article-title":"Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-platinum, and megestrol acetate","volume":"63","author":"Lovecchio","year":"1984","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00006250-198602000-00019","article-title":"Melphalan, 5-Fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma","volume":"67","author":"Piver","year":"1986","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF80","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0090-8258(88)80012-X","article-title":"Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status","volume":"31","author":"Ayoub","year":"1988","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0090-8258(89)90016-4","article-title":"Treatment of recurrent and metastic endometrial cancer with cisplatin doxorubicin, cyclophosphamide, and megestrol acetate","volume":"35","author":"Hoffman","year":"1989","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF82","first-page":"1033","article-title":"Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate","volume":"78","author":"Fung","year":"1991","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/gyno.1995.0015","article-title":"Cisplatin, adriamycin, etoposide, megesterol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma","volume":"59","author":"Cornelison","year":"1995","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF84","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1006\/gyno.1996.0074","article-title":"Chemotherapy plus sequential hormone therapy for advanced and recurrent endometrial carcinoma: a phase II study","volume":"60","author":"Pinelli","year":"1996","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF85","first-page":"1563","article-title":"Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology","volume":"150","author":"Carmeci","year":"1997","journal-title":"American Journal of Pathology"},{"key":"10.1053\/beog.2000.0189_RF86","first-page":"530","article-title":"Differences in estrogen receptor \u03b1 variant messenger RNAs between normal human breast tissue and primary breast carcinomas","volume":"65","author":"van Dijk","year":"2000","journal-title":"Cancer Research"},{"key":"10.1053\/beog.2000.0189_RF87","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/gyno.1998.5281","article-title":"Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma","volume":"72","author":"Nola","year":"1999","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF88","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/0002-9378(90)91293-L","article-title":"Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model","volume":"162","author":"Mortel","year":"1990","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2000.0189_RF89","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/gyno.1996.0305","article-title":"Mutations of the estrogen receptor in endometrial carcinoma: evidence of an association with high tumor grade","volume":"63","author":"Assikis","year":"1996","journal-title":"Gynecologic Oncology"},{"key":"10.1053\/beog.2000.0189_RF90","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0029-7844(95)00113-6","article-title":"Mutational analysis of the estrogen-receptor gene in endometrial carcinoma","volume":"86","author":"Kohler","year":"1995","journal-title":"Obstetrics and Gynecology"}],"container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693400901895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693400901895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T05:38:17Z","timestamp":1621143497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693400901895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["S1521693400901895"],"URL":"https:\/\/doi.org\/10.1053\/beog.2000.0189","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}